NetworkNewsBreaks – Lexaria Bioscience Corp. (LX
Post# of 721
(Total Views: 237)
Posted On: 07/28/2017 7:12:39 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (LXRP) Well-Positioned for Growth as First Mover in Canada’s Cannabinoid Market
Among players in Canada’s emerging cannabinoid market, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is well-positioned for growth. Lexaria is a revenue-generating company engaged in developing and out-licensing proprietary technology for delivering bioactive compounds, including cannabinoids, and the company’s products utilize this patented lipophilic technology, which has been proven to enhance the bioavailability of orally ingested cannabinoids and also improve their taste.
“With full legalization expected in 2018, the Canadian market for cannabis extracts and oils is expected to top C$1.6 billion by 2020. Lexaria is at the forefront of innovation in the biosciences sector as pioneering biopharmaceutical companies in Canada and elsewhere work to research and develop healthy cannabinoid products. Investment capital in these “plant-to-bloodstream” companies is expected to grow exponentially. As a first mover into this space, Lexaria is well-positioned for increasing market share and revenue.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Among players in Canada’s emerging cannabinoid market, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is well-positioned for growth. Lexaria is a revenue-generating company engaged in developing and out-licensing proprietary technology for delivering bioactive compounds, including cannabinoids, and the company’s products utilize this patented lipophilic technology, which has been proven to enhance the bioavailability of orally ingested cannabinoids and also improve their taste.
“With full legalization expected in 2018, the Canadian market for cannabis extracts and oils is expected to top C$1.6 billion by 2020. Lexaria is at the forefront of innovation in the biosciences sector as pioneering biopharmaceutical companies in Canada and elsewhere work to research and develop healthy cannabinoid products. Investment capital in these “plant-to-bloodstream” companies is expected to grow exponentially. As a first mover into this space, Lexaria is well-positioned for increasing market share and revenue.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼